Ramiven 150mg Tablet contains Abemaciclib 150mg, an oral prescription cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor used in the treatment of hormone receptor-positive (HR-positive), HER2-negative breast cancer. Current Indian pharmacy listings identify Ramiven 150mg as an Abemaciclib 150mg product marketed by Eli Lilly and Company India Pvt Ltd.
Abemaciclib is used in approved treatment settings for certain early, advanced, or metastatic HR-positive/HER2-negative breast cancers, either with endocrine therapy or, in specific advanced/metastatic settings, as monotherapy. In the United States, the reference brand for abemaciclib is Verzenio®, marketed by Eli Lilly.
Ramiven 150mg is therefore commercially relevant for searches around Abemaciclib 150mg, Abemaciclib 150mg Tablet, CDK4/6 inhibitor, HR-positive HER2-negative breast cancer treatment, Generic Abemaciclib, Verzenio alternative and Abemaciclib price. The product should be used only under appropriate oncology supervision.
Ramiven 150mg is an oral targeted cancer medicine containing Abemaciclib.
Abemaciclib belongs to the CDK4/6 inhibitor class. CDK4 and CDK6 are proteins involved in controlling progression through the cell cycle. In certain breast cancers, abnormal activity of these proteins contributes to continued cancer-cell proliferation.
By inhibiting CDK4 and CDK6, Abemaciclib can interfere with cell-cycle progression and help slow the growth and spread of susceptible cancer cells.
Ramiven/Abemaciclib is used for eligible patients with HR-positive, HER2-negative breast cancer.
Depending on the approved indication and treatment setting, Abemaciclib may be used for:
The exact approved indications differ by jurisdiction and product labeling.
Abemaciclib selectively inhibits CDK4 and CDK6, two proteins that regulate cell-cycle progression.
In susceptible breast cancer cells, blocking these proteins can prevent progression from the G1 phase toward the DNA-synthesis phase of the cell cycle. This reduces cancer-cell proliferation and can help control tumor growth.
This targeted mechanism makes Abemaciclib different from conventional cytotoxic chemotherapy.
Ramiven is particularly relevant to treatment of hormone receptor-positive, HER2-negative breast cancer.
For appropriate patients, Abemaciclib may be combined with endocrine therapy such as tamoxifen, an aromatase inhibitor, or fulvestrant, depending on the treatment setting.
The FDA-approved starting dose for certain adjuvant early-breast-cancer patients is 150mg twice daily with tamoxifen or an aromatase inhibitor, while dosing in advanced/metastatic disease depends on whether Abemaciclib is being used alone or with endocrine therapy.
Ramiven contains Abemaciclib, while Verzenio® is the U.S. reference brand for Abemaciclib. FDA records identify Verzenio as an Abemaciclib product marketed by Eli Lilly.
Therefore, commercially relevant search terms can include:
Ramiven 150mg → Abemaciclib 150mg → Verzenio 150mg → Generic Abemaciclib 150mg → Abemaciclib Alternative → CDK4/6 Inhibitor
However, “generic Verzenio” should only be used when the particular product has the appropriate generic regulatory status in the target market. Ramiven itself is a branded Abemaciclib product, not simply a generic label for Verzenio.
The appropriate Abemaciclib dose depends on the cancer type, treatment setting, combination therapy, patient response and tolerability.
A 150mg tablet is an established Abemaciclib strength and may be prescribed as part of a twice-daily regimen or adjusted according to the treating oncologist’s instructions. FDA information identifies 150mg twice daily as the recommended starting dose for certain high-risk node-positive early breast cancer patients receiving endocrine therapy.
Ramiven should be taken exactly as prescribed. Swallow the tablet whole with water. Do not crush, chew or alter the tablet unless specifically instructed by a healthcare professional.
Do not increase, reduce or stop the dose without consulting the treating oncologist.
Abemaciclib can cause adverse effects and requires appropriate medical monitoring.
Commonly reported adverse reactions include:
Serious adverse reactions can also occur, including severe diarrhea, neutropenia, hepatotoxicity, venous thromboembolism and interstitial lung disease/pneumonitis. Patients should promptly contact their healthcare provider if they develop severe diarrhea, fever, breathing difficulties, chest symptoms or other concerning reactions.
Treatment with Abemaciclib generally requires regular oncology follow-up.
Depending on the patient’s treatment regimen, monitoring may include:
Abemaciclib can also interact with other medicines, particularly drugs affecting CYP3A metabolism. Patients should provide their oncologist and pharmacist with a complete list of prescription medicines, OTC products and supplements.
Abemaciclib is commonly combined with endocrine therapy in HR-positive, HER2-negative breast cancer.
Depending on the indication, combinations may include:
The choice depends on the patient’s menopausal status, previous treatment, cancer stage, recurrence risk and other clinical factors.
Ramiven 150mg Tablet is a prescription oncology medicine. Current Indian pharmacy listings show Ramiven 150mg containing Abemaciclib 150mg and available in tablet packs, with prescription requirements.
Customers searching for Ramiven 150mg Tablet, Abemaciclib 150mg, Buy Ramiven 150mg, Buy Abemaciclib 150mg, Ramiven 150mg Price, Abemaciclib 150mg Price, Generic Abemaciclib 150mg, Verzenio Alternative, Abemaciclib Supplier and related transactional terms should obtain the medicine through an appropriately licensed pharmacy or authorized pharmaceutical supplier.
Availability, prescription requirements, importation and dispensing regulations vary across the USA, UK, UAE/Dubai, Australia, Singapore, Thailand, China and Russia.
Ramiven 150mg contains Abemaciclib and is used for eligible HR-positive, HER2-negative breast cancer, including certain high-risk early breast cancers and advanced or metastatic disease.
The generic name is Abemaciclib.
Ramiven 150mg contains Abemaciclib 150mg as its active ingredient.
Both contain Abemaciclib, but Ramiven and Verzenio are different branded products. Verzenio is the U.S. reference brand marketed by Eli Lilly.
Yes. Abemaciclib inhibits cyclin-dependent kinases 4 and 6 (CDK4/6), which are involved in cell-cycle regulation.
Abemaciclib is used for hormone receptor-positive (HR+), HER2-negative breast cancer in specific approved treatment settings.
Yes. Depending on the indication, Abemaciclib can be combined with tamoxifen, an aromatase inhibitor or fulvestrant.
Abemaciclib is approved as monotherapy for certain adults with HR-positive, HER2-negative advanced or metastatic breast cancer following endocrine therapy and prior chemotherapy in the metastatic setting.
It blocks CDK4 and CDK6, interfering with cell-cycle progression and slowing the multiplication of susceptible breast cancer cells.
Ramiven is a prescription anticancer medicine. It should be purchased only through an appropriately licensed pharmacy or authorized pharmaceutical supplier and used under oncology supervision.
Yes. Abemaciclib treatment commonly requires monitoring of blood counts and liver function, along with assessment for other treatment-related complications.
Diarrhea, neutropenia, infections, nausea, fatigue, anemia, headache, abdominal symptoms and increased liver enzymes are among the reported adverse reactions.
Medical Disclaimer: This product information is provided for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis or treatment. Ramiven (Abemaciclib) is a prescription anticancer medicine requiring specialist medical supervision. Treatment selection, dosage, combination therapy, monitoring and approved indications depend on the patient’s cancer type and clinical circumstances and may vary by country. Abemaciclib can cause serious adverse reactions, including severe diarrhea, neutropenia, liver toxicity, venous thromboembolism and interstitial lung disease/pneumonitis. Always follow the official prescribing information for the specific product and consult a qualified oncologist before starting, stopping or changing treatment.
Last Updated: August 23, 2026
Orders ship from our India Head Office within 1–2 business days of confirmation. We include full customs documentation — HS codes, certificates of origin, and pharmaceutical export permits.
Estimated delivery: 3–7 business days to UK. 7–10 business days to UAE, Saudi Arabia and Gulf countries. 10–15 days for USA and Asian countries.
All packages arrive in plain, unmarked brown boxes. No pharmacy name or medication details on the outside.
Ramiven 150mg Tablet
Reviews
There are no reviews yet